• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

33.92 -0.39 (-1.14%)
Official Closing Price Updated: 7:00 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,025,551
Open 34.35
Bid (Size) 33.70 (200)
Ask (Size) 34.05 (3,400)
Prev. Close 34.31
Today's Range 33.72 - 34.35
52wk Range 12.46 - 37.34
Shares Outstanding 1,110,352,397
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Viatris at a Crossroads: Transitioning from Generic Giant to Specialty Powerhouse
February 10, 2026
February 10, 2026 Introduction As of February 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a pivotal juncture. Five years after its high-profile inception, the company has shed its skin as a... 
Via Finterra
Topics Economy World Trade
News headline image
Teva (TEVA) Q4 2024 Earnings Call Transcript ↗
February 05, 2026
Teva (TEVA) Q4 2024 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings

Performance

YTD
+9.6%
+9.6%
1 Month
+4.5%
+4.5%
3 Month
+32.8%
+32.8%
6 Month
+93.4%
+93.4%
1 Year
+107.6%
+107.6%

More News

Read More
News headline image
Teva (TEVA) Q3 2024 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings
TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) Shows Perfect Technical Setup for Breakout ↗
January 28, 2026
Via Chartmill
Why Is TEVA Stock Rising Pre-Market Today? ↗
January 12, 2026
Via Stocktwits
News headline image
Harel Insurance Sold $330 Million of Invesco KBW Bank ETF ↗
February 05, 2026
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Aytu BioPharma AYTU Q2 2026 Earnings Transcript ↗
February 03, 2026
Via The Motley Fool
News headline image
Bank ETF Up 20% in a Year, but This Fund Just Cut a $10 Million Position ↗
January 29, 2026
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Teva (TEVA) Q3 2025 Earnings Call Transcript ↗
January 28, 2026
Via The Motley Fool
Topics Earnings
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
January 28, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
January 28, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The $100 Billion Milestone: Johnson & Johnson Pivots from 'Steady' 2025 to Growth-Focused 2026
January 27, 2026
Via MarketMinute
Topics Earnings Economy Government
News headline image
Will Forte Teams Up with Teva to Get Real About Huntington’s Disease with ‘Honestly HD’
January 27, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
January 20, 2026
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
AJOVY® (fremanezumab-vfrm) Significantly Reduced Monthly Migraine and Headache Days in Children and Adolescents with Episodic Migraine Compared to Placebo in the SPACE Trial; Results Published in New England Journal of Medicine
January 14, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation
January 14, 2026
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivering Growth and Transforming through Innovation
January 11, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From Royalty Pharma plc
Via GlobeNewswire
News headline image
Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo
January 11, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story ↗
December 27, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive
December 24, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026 ↗
December 24, 2025
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
December 19, 2025
From Teva Pharmaceutical Industries Ltd
Via GlobeNewswire
News headline image
My Top 10 Portfolio Holdings for 2026 ↗
December 19, 2025
Via The Motley Fool
Topics Stocks

Frequently Asked Questions

Is Teva Pharmaceutical Industries Limited American Depositary Shares publicly traded?
Yes, Teva Pharmaceutical Industries Limited American Depositary Shares is publicly traded.
What exchange does Teva Pharmaceutical Industries Limited American Depositary Shares trade on?
Teva Pharmaceutical Industries Limited American Depositary Shares trades on the New York Stock Exchange
What is the ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares?
The ticker symbol for Teva Pharmaceutical Industries Limited American Depositary Shares is TEVA on the New York Stock Exchange
What is the current price of Teva Pharmaceutical Industries Limited American Depositary Shares?
The current price of Teva Pharmaceutical Industries Limited American Depositary Shares is 33.92
When was Teva Pharmaceutical Industries Limited American Depositary Shares last traded?
The last trade of Teva Pharmaceutical Industries Limited American Depositary Shares was at 02/12/26 07:00 PM ET
What is the market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares?
The market capitalization of Teva Pharmaceutical Industries Limited American Depositary Shares is 37.66B
How many shares of Teva Pharmaceutical Industries Limited American Depositary Shares are outstanding?
Teva Pharmaceutical Industries Limited American Depositary Shares has 38B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap